Table 3.
Different factors influencing seroconversion rate in allograft recipient patients.
| Characteristics | Seroconversion | |||
|---|---|---|---|---|
| Yes | No | p Value | ||
| Post-transplant interval (months) associated seroconversion | 2–60 | 73 (87.95%) | 10 (12.04%) | 0.71 |
| 60–120 | 72 (84.7%) | 13 (15.3%) | ||
| 120–180 | 31 (86.1%) | 5 (13.8%) | ||
| >180 | 17 (94.4%) | 1 (5.5%) | ||
| BMI (kg/m2) associated seroconversion | <18.4 | n = 37 (90.2%) | n = 4 (9.7%) | 0.23 |
| 18.4–24.99 | n = 72 (82.75%) | n = 15 (17.24%) | ||
| 25.29–29.99 | n = 62 (92.5%) | n = 5 (7.4%) | ||
| >30 | n = 22 (81.5%) | n = 5 (18.51%) | ||
| Age-wise (Year) seroconversion $ | 18–45 | n = 130 (90.27%) | n = 14 (9.72%) | 0.074 |
| 46–60 | n= 56 (82.35%) | n = 12 (17.46%) | ||
| >60 | n = 7 (70%) | n = 3 (30%) | ||
| Vaccine brand associated seroconversion | Covishield™ | n= 32 (76.19%) | n = 10 (23.80%) | 0.003 |
| Titer: 1831.10 (81.26–7522.56) AU/mL | ||||
| Covaxin™ | n = 16 (84.21%) | n = 3 (15.78%) | 0.016 | |
| Titer: 1373.90 (IQR: 507.80–3765.10) AU/mL | ||||
| Blood group associated seroconversion | A+ | n = 47 (87.03%) | n = 7 (12.96%) | 0.488 |
| B+ | n = 62 (82.66%) | n = 13 (17.33%) | ||
| AB+ | n = 27 (93.10%) | n = 2 (6.89%) | ||
| O+ | n = 57 (89.06%) | n = 7 (10.93%) | ||
| Immunosuppression associated seroconversion | Tacrolimus + MMF + Steroid | n = 184 (86.79%) | n = 28 (13.20%) | 1.00 |
| Cyclosporin + MMF + Steroid | n = 9 (90%) | n = 1 (10%) | ||
| Serum creatinine | <1.4 | 120 (87.59%) | 17 (12.40%) | 0.83 |
| >1.4 | 73 (85.88%) | 12 (14.11%) | ||
$ As per ICMR guideline of vaccination.